Association between cardiac dysfunction and late gadolinium enhancement confined to the LV intramural region in patients with hypertrophic cardiomyopathy. [PDF]
Yang Z +7 more
europepmc +1 more source
Deep learning approaches to predict late gadolinium enhancement and clinical outcomes in suspected cardiac sarcoidosis. [PDF]
Azoulay LD +8 more
europepmc +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
Diagnostic accuracy of late gadolinium enhancement cardiac MRI for coronary artery disease in patients with reduced left ventricular ejection fraction. [PDF]
Desroche LM +22 more
europepmc +1 more source
Potential predictive value of myocardial strain and strain rate for late gadolinium enhancement in children with a history of Kawasaki disease. [PDF]
Zhang N +10 more
europepmc +1 more source
Late Gadolinium Enhancement and Higher Risk of Arrhythmias
Alter, Peter, Rupp, Heinz
openaire +1 more source
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli +17 more
wiley +1 more source
Detection of late gadolinium enhancement in patients with hypertrophic cardiomyopathy using machine learning. [PDF]
Akita K +7 more
europepmc +1 more source
Role of late gadolinium enhancement in the risk stratification of pediatric hypertrophic cardiomyopathy: based on a Chinese cohort. [PDF]
Chen X +17 more
europepmc +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source

